Mereo BioPharma Group plc (MREO): R&D Expense
$17.77M
Year ended 2025-12-31
$15.02M
Trailing 12 months to 2026-06-30
-15.5%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $17.77M | -15.1% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $20.93M | +20.2% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $17.42M | -40.9% | 2025-03-26, From 2023-01-01 |
| 2022-12-31 | $29.46M | n/a | 2024-03-27, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | $17.77M | -15.1% |
| Lipella Pharmaceuticals Inc. (LIPO) | 2024-12-31 | $3.61M | +18.9% |
| Quantum Cyber N.V. (QUCY) | 2025-12-31 | $4.91M | -14.2% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $67.75M | -0.2% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $19.24M | -37.8% |
| Scienture Holdings, Inc. (SCNX) | 2025-12-31 | $1.96M | -12.5% |
| PMGC Holdings Inc. (ELAB) | 2025-12-31 | $147.0K | +40.5% |
| Vaccinex, Inc. (VCNX) | 2024-12-31 | $12.54M | -24.3% |
| Medicinova Inc (MNOV) | 2025-12-31 | $6.70M | -1.5% |
Compare MREO, LIPO, QUCY, SLN side by side · Screen every company in Pharmaceutical Preparations ↗